<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药知说 | wechat-feeds</title><link>http://MzI0NzM5NjM4Mw.favicon.privacyhide.com/favicon.ico</link><description>生物医药知识产权信息发布，包括医药专利，医药商标，医药网络域名等；生物医药知识产权数据分析，包括医药专利分析，医药商标与域名的冲突与分析，疾病治疗领域专利分析；生物医药知识产权信息检索，包括专利检索，商标检索，以及网络知识产权信息检索</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 25 Jan 2021 23:50:32 +0800</pubDate><image><url>http://MzI0NzM5NjM4Mw.favicon.privacyhide.com/favicon.ico</url><title>药知说 | wechat-feeds</title><link>http://MzI0NzM5NjM4Mw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>泊马度胺Pomalyst(Pomalidomide)的又一件专利在日本获得保护期延长</title><link>https://mp.weixin.qq.com/s/OLGCsDMaYU_rRAR_jddRwg</link><description></description><content:encoded><![CDATA[泊马度胺Pomalyst(Pomalidomide)的又一件专利在日本获得保护期延长]]></content:encoded><pubDate>Mon, 31 Aug 2020 16:39:50 +0800</pubDate></item><item><title>布美兰肽 Bremelanotide（Vyleesi）被公示专利保护期延长</title><link>https://mp.weixin.qq.com/s/PXXQyPVo4axI32SDPusggA</link><description></description><content:encoded><![CDATA[布美兰肽 Bremelanotide（Vyleesi）被公示专利保护期延长]]></content:encoded><pubDate>Thu, 27 Aug 2020 11:08:36 +0800</pubDate></item><item><title>吡仑帕奈（卫克泰）Perampanel(Fycompa)在韩国获准专利保护期延长</title><link>https://mp.weixin.qq.com/s/GV6fBcxJxnPbnMBSphXOyw</link><description></description><content:encoded><![CDATA[吡仑帕奈（卫克泰）Perampanel(Fycompa)在韩国获准专利保护期延长]]></content:encoded><pubDate>Wed, 26 Aug 2020 07:18:08 +0800</pubDate></item><item><title>诺华的布洛赛珠单抗Beovu®(Brolucizumab)的登记专利在加拿大获专利保护期延长</title><link>https://mp.weixin.qq.com/s/rlZnnSzFYDf92OBATitR4g</link><description></description><content:encoded><![CDATA[诺华的布洛赛珠单抗Beovu®(Brolucizumab)的登记专利在加拿大获专利保护期延长]]></content:encoded><pubDate>Sun, 16 Aug 2020 10:46:53 +0800</pubDate></item><item><title>泊马度胺Pomalyst(Pomalidomide)的专利在日本获得保护期延长</title><link>https://mp.weixin.qq.com/s/0tDm39iOTTAjSDBdfPuHqw</link><description></description><content:encoded><![CDATA[泊马度胺Pomalyst(Pomalidomide)的专利在日本获得保护期延长]]></content:encoded><pubDate>Sat, 15 Aug 2020 12:06:59 +0800</pubDate></item><item><title>巴洛沙韦玛波西酯在韩国获准专利保护期延长</title><link>https://mp.weixin.qq.com/s/4phQUh-WTPd1rOgHFqrM3w</link><description></description><content:encoded><![CDATA[巴洛沙韦玛波西酯在韩国获准专利保护期延长]]></content:encoded><pubDate>Fri, 31 Jul 2020 16:38:24 +0800</pubDate></item><item><title>拜耳的达洛鲁胺Nubeqa®(darolutamide)的登记专利在加拿大获专利保护期延长</title><link>https://mp.weixin.qq.com/s/asxkmCtIgqPk-XnfHOo5FQ</link><description></description><content:encoded><![CDATA[拜耳的达洛鲁胺Nubeqa®(darolutamide)的登记专利在加拿大获专利保护期延长]]></content:encoded><pubDate>Wed, 29 Jul 2020 09:32:30 +0800</pubDate></item><item><title>罗莫佐单抗Evenity(romosozumab)105mg注射液的专利在日本获得保护期延长</title><link>https://mp.weixin.qq.com/s/Im9BZOOcmcLX1qSRFM1tag</link><description></description><content:encoded><![CDATA[罗莫佐单抗Evenity(romosozumab)105mg注射液的专利在日本获得保护期延长]]></content:encoded><pubDate>Mon, 20 Jul 2020 20:36:39 +0800</pubDate></item><item><title>2020年6月份美国FDA 临时批准了两款提出Piv挑战的首仿药</title><link>https://mp.weixin.qq.com/s/r04JYNok0NEfnzhUuiIwNQ</link><description></description><content:encoded><![CDATA[2020年6月份美国FDA 临时批准了两款提出Piv挑战的首仿药]]></content:encoded><pubDate>Thu, 16 Jul 2020 09:19:02 +0800</pubDate></item><item><title>疫期药品专利在线公益系列讲座</title><link>https://mp.weixin.qq.com/s/8o4CKZBX8awQGN3mPvFbww</link><description></description><content:encoded><![CDATA[疫期药品专利在线公益系列讲座]]></content:encoded><pubDate>Sat, 22 Feb 2020 18:22:09 +0800</pubDate></item></channel></rss>